FT3967385

FT3967385 (administered at concentrations ranging from 0 to 15000 nM for 30 min in the cell homogenate system; and at concentrations ranging from 0 to 625 nM for 4 h in the intact cell system) binds to endogenous USP30 in SH-SY5Y neuroblastoma cells at concentrations >100 nM^[1].
FT3967385 (200 nM; 1-4 h) mimics the phenotype of USP30 knockout in hTERT-RPE1 YFP-Parkin cells by enhancing TOM20 ubiquitination after antimycin A and oligomycin A (AO)-induced mitochondrial depolarization, confirming its specific inhibitory effect on USP30^[1].
FT3967385 (100-200 nM; 4-24 h) enhances the ubiquitination of TOM20 in SHSY5Y cells expressing endogenous Parkin after AO-induced mitochondrial depolarization^[1].
FT3967385 (100-200 nM; 4-24 h) enhances the accumulation of phosphorylated Ser65, SYNJ2BP ubiquitin, and the ubiquitination of specific mitochondrial proteins (including members of the VDAC family) in depolarized SHSY5Y cells, thereby accelerating the PINK1-dependent signaling cascade of mitophagy^[1].
FT3967385 (200-500 nM; 96 h) significantly increases the basal mitophagic flux in SHSY5Y-mitoQC cells over a 96 h treatment period^[1].
Treatment with FT3967385 (200-500 nM; 96 h, administered once every 24 h) for 96 h enhances the basal mitophagic flux of SHSY5Y-mitoQC cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.